Novel gene editing Biomay regularly launches mRNA-encoded spCas9 and optimized variants, indicating strong capabilities in plasmid DNA and mRNA production for genome editing tools. This creates cross-selling opportunities with customers needing ready-to-use nuclease products and related gene-editing reagents.

Vienna expansion Recent facility expansions in Vienna and the establishment of a Western Europe manufacturing footprint suggest increased production capacity and regional reliability. This supports pursuing customers requiring scalable GMP plasmid DNA, mRNA, and recombinant proteins with closer geographic support.

CRISPR portfolio Launch of FDA-grade CRISPR/Cas9 nuclease and mRNA-encoded Cas9 positions Biomay as a credible supplier for genome-editing workflows. Target customers include biotech firms and research institutes seeking off-the-shelf, quality-assured genome-editing components.

Quality and flexibility Biomay emphasizes GMP manufacturing, flexibility, and reliability from gene construction to market supply. This aligns with risk-averse customers in biotech and pharma seeking dependable suppliers for plasmid DNA, mRNA, and recombinant proteins.

Strategic partnerships Past collaborations with BioNTech and industry partners highlight a track record in supporting large-scale biopharma programs. This opens conversations with mid-size biotech firms and contract manufacturers aiming to scale production for mRNA and related products.